Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: SC Prevention of severe thrombocytopenia after myelosuppressive chemotherapy; Reduce the need for platelet transfusions after myelosuppressive chemotherapy 50 mcg/kg/day. Give initial dose 6-24 hr after the last antineoplastic dose and continue for up to a max of 21 days. Discontinue at least 2 days before the next chemotherapy cycle.
Do not use after myeloablative chemotherapy and bone marrow transplantation.
Special Precautions
History or signs of heart failure. Monitor fluid and electrolyte balance in patients on prolonged diuretic therapy. Pre-existing papilloedema or CNS tumours, pre-existing pericardial effusions or ascites. Hepatic, renal or respiratory impairment. History of stroke or thromboembolic disorders. Pregnancy and lactation.
Adverse Reactions
Tachycardia, oedema, palpitation, cardiomegaly, vasodilation, syncope, atrial arrhythmia; headache, dizziness, fever, insomnia, fatigue; rash; fluid retention; nausea/vomiting, diarrhoea, oral moniliasis; dilutional anaemia; weakness, arthralgia, periostitis; conjunctival inj/redness/swelling, papilloedema; dyspnoea, rhinitis, cough, pharyngitis; wt gain; pleural effusion.
Potentially Fatal: Anaphylactoid reactions.
Drug Interactions
Increased risk of adverse CV effects with diuretics (due to hypokalaemia).
ATC Classification
L03AC02 - oprelvekin ; Belongs to the class of interleukins. Used as immunostimulants.
Disclaimer: This information is independently developed by CIMS based on oprelvekin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in